Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alzamend Neuro Inc (ALZN)

Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,077
  • Shares Outstanding, K 3,805
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,510 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta -0.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/26
See More
  • Average Estimate -0.67
  • Number of Estimates 1
  • High Estimate -0.67
  • Low Estimate -0.67
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7100 +5.26%
on 03/20/26
2.3565 -23.62%
on 03/16/26
-0.2900 (-13.88%)
since 02/24/26
3-Month
1.5800 +13.92%
on 02/17/26
2.5350 -28.99%
on 01/22/26
-0.2500 (-12.20%)
since 12/24/25
52-Week
1.5800 +13.92%
on 02/17/26
10.1700 -82.30%
on 03/25/25
-7.3800 (-80.39%)
since 03/24/25

Most Recent Stories

More News
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

ATLANTA , March 16, 2026 /PRNewswire/ --  Alzamend Neuro, Inc. (Nasdaq: ALZN) (" Alzamend "), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment...

ALZN : 1.8000 (-3.23%)
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

ATLANTA , Nov. 19, 2025 /PRNewswire/ --  Alzamend Neuro, Inc. (Nasdaq: ALZN) (" Alzamend "), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment...

ALZN : 1.8000 (-3.23%)
Alzamend Neuro Issues New Common Stock Shares

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alzamend...

ALZN : 1.8000 (-3.23%)
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in...

ALZN : 1.8000 (-3.23%)
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025,...

ALZN : 1.8000 (-3.23%)
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

ALZN : 1.8000 (-3.23%)
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

ALZN : 1.8000 (-3.23%)
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

ALZN : 1.8000 (-3.23%)
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

ALZN : 1.8000 (-3.23%)
Alzamend Neuro Announces Reverse Stock Split

ALZN : 1.8000 (-3.23%)

Business Summary

Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline...

See More

Key Turning Points

3rd Resistance Point 1.9533
2nd Resistance Point 1.9067
1st Resistance Point 1.8533
Last Price 1.8000
1st Support Level 1.7533
2nd Support Level 1.7067
3rd Support Level 1.6533

See More

52-Week High 10.1700
Fibonacci 61.8% 6.8886
Fibonacci 50% 5.8750
Fibonacci 38.2% 4.8614
Last Price 1.8000
52-Week Low 1.5800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.